Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00096798 · ClinicalTrials.gov registry record · Phase 3
Ethyl Eicosapentanoic Acid (Ethyl-EPA) for Treating Major Depression
A Phase 3 study, sponsored by National Center for Complementary and Integrative Health (NCCIH).
- Completed
- Registry status
- Phase 3
- Development phase
- 80
- Enrollment target
NCT00096798 is a Phase 3 study that has completed, run by National Center for Complementary and Integrative Health (NCCIH). The registered enrollment target is 80 participants.
The verdict
NCT00096798, a Phase 3 study, has completed, sponsored by National Center for Complementary and Integrative Health (NCCIH).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 80 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the effectiveness of ethyl-eicosapentanoic acid (ethyl-EPA), an omega-3 fatty acid, in treating depression.
Interventions
- DRUG Ethyl-eicosapentanoic acid (ethyl-EPA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2001-09 |
| Est. Completion | 2007-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00096798
The ClinicalTrials.gov registry entry for NCT00096798 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Center for Complementary and Integrative Health (NCCIH), which has 203 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ethyl-eicosapentanoic acid (ethyl-EPA) is the first listed.
NCT00096798 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00096798 about?
NCT00096798 is a clinical study titled "Ethyl Eicosapentanoic Acid (Ethyl-EPA) for Treating Major Depression". The purpose of this study is to examine the effectiveness of ethyl-eicosapentanoic acid (ethyl-EPA), an omega-3 fatty acid, in treating depression.
What is the current status of trial NCT00096798?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 80 participants. The study started on 2001-09. Estimated completion is 2007-08.
What interventions are being tested in trial NCT00096798?
The interventions under investigation include: Ethyl-eicosapentanoic acid (ethyl-EPA) (DRUG).
Who is sponsoring clinical trial NCT00096798?
This trial is sponsored by National Center for Complementary and Integrative Health (NCCIH), which has 203 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.